GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kiora Pharmaceuticals Inc (NAS:KPRX) » Definitions » Return-on-Tangible-Asset

KPRX (Kiora Pharmaceuticals) Return-on-Tangible-Asset : -42.77% (As of Sep. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Kiora Pharmaceuticals Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Kiora Pharmaceuticals's annualized Net Income for the quarter that ended in Sep. 2024 was $-13.65 Mil. Kiora Pharmaceuticals's average total tangible assets for the quarter that ended in Sep. 2024 was $31.92 Mil. Therefore, Kiora Pharmaceuticals's annualized Return-on-Tangible-Asset for the quarter that ended in Sep. 2024 was -42.77%.

The historical rank and industry rank for Kiora Pharmaceuticals's Return-on-Tangible-Asset or its related term are showing as below:

KPRX' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -243.63   Med: -181.24   Max: 25.35
Current: 25.35

During the past 12 years, Kiora Pharmaceuticals's highest Return-on-Tangible-Asset was 25.35%. The lowest was -243.63%. And the median was -181.24%.

KPRX's Return-on-Tangible-Asset is ranked better than
97.8% of 1503 companies
in the Biotechnology industry
Industry Median: -39.32 vs KPRX: 25.35

Kiora Pharmaceuticals Return-on-Tangible-Asset Historical Data

The historical data trend for Kiora Pharmaceuticals's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kiora Pharmaceuticals Return-on-Tangible-Asset Chart

Kiora Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only -108.72 -214.47 -243.63 -157.07 -195.03

Kiora Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -284.07 -151.60 279.33 -27.08 -42.77

Competitive Comparison of Kiora Pharmaceuticals's Return-on-Tangible-Asset

For the Biotechnology subindustry, Kiora Pharmaceuticals's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kiora Pharmaceuticals's Return-on-Tangible-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kiora Pharmaceuticals's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Kiora Pharmaceuticals's Return-on-Tangible-Asset falls into.



Kiora Pharmaceuticals Return-on-Tangible-Asset Calculation

Kiora Pharmaceuticals's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-12.514/( (7.935+4.898)/ 2 )
=-12.514/6.4165
=-195.03 %

Kiora Pharmaceuticals's annualized Return-on-Tangible-Asset for the quarter that ended in Sep. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Sep. 2024 )  (Q: Jun. 2024 )(Q: Sep. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Sep. 2024 )  (Q: Jun. 2024 )(Q: Sep. 2024 )
=-13.652/( (32.013+31.822)/ 2 )
=-13.652/31.9175
=-42.77 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Sep. 2024) net income data.


Kiora Pharmaceuticals  (NAS:KPRX) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Kiora Pharmaceuticals Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Kiora Pharmaceuticals's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Kiora Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
332 Encinitas Boulevard, Suite 102, Encinitas, CA, USA, 92024
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
Executives
Carmine N. Stengone director 10578 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121
Aron Shapiro director C/O EYEGATE PHARMACEUTICALS INC., 271 WAVERLY OAKS RD., STE 108, WALTHAM MA 02452
Praveen Tyle director ONE BAUSCH & LOMB PLACE, ROCHESTER NY 14604
Melissa Tosca officer: EVP of Finance C/O KIORA PHARMACEUTICALS, INC., 1371 EAST 2100 SOUTH, SUITE 200, SALT LAKE CITY UT 84105
Eric Joseph Daniels officer: Chief Development Officer C/O EYEGATE PHARMACEUTICALS INC., 271 WAVERLY OAKS RD., STE 108, WALTHAM MA 02452
Brian M. Strem director, officer: President and CEO C/O EYEGATE PHARMACEUTICALS INC., 271 WAVERLY OAKS RD., STE 108, WALTHAM MA 02452
Erin Parsons director 97 WILLISTON RD, BROOKLINE MA 02445
Susan L. Drexler officer: Interim CFO 630 W. GERMANTOWN PIKE, SUITE 215, PLYMOUTH MEETING PA 19462
David Hollander director C/O AERIE PHARMACEUTICALS, INC., 4301 EMPEROR BLVD., SUITE 400, DURHAM NC 27703
Armistice Capital Master Fund Ltd. director, 10 percent owner C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital, Llc director, 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Steven Boyd director, 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Kenneth L Gayron director 75 NETWORK DRIVE, BURLINGTON MA 34212
Franz Obermayr officer: Acting CEO C/O EYEGATE PHARMACEUTICALS, INC., 271 WAVERLEY OAKS ROAD, SUITE 108, WALTHAM MA 02452
Thomas Hancock director C/O BURNS & LEVINSON LLP, 125 SUMMER STREET, BOSTON MA 02110